Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
CONCLUSION: Adjuvant chemotherapy was associated with an overall survival benefit for patients with inadequately-staged, grade 2 stage I ovarian endometrioid adenocarcinoma. A possible benefit for inadequately-staged patients with grade 3 tumors cannot be excluded.
PMID: 31839340 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Nasioudis D, Latif NA, Simpkins F, Cory L, Giuntoli RL, Haggerty AF, Morgan MA, Ko EM Tags: Gynecol Oncol Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Databases & Libraries | Endometrial Cancer | Endometrioid Carcinoma | Ovarian Cancer | Ovaries | Science | Statistics